PMC:3342329 / 26255-26766 JSONTXT

{"project":"test3","denotations":[{"id":"T9001","span":{"begin":498,"end":502},"obj":"Protein"},{"id":"T9000","span":{"begin":479,"end":485},"obj":"Protein"},{"id":"T8999","span":{"begin":321,"end":325},"obj":"Protein"},{"id":"T8998","span":{"begin":175,"end":179},"obj":"Protein"},{"id":"T8997","span":{"begin":161,"end":171},"obj":"Negative_regulation"},{"id":"T8996","span":{"begin":70,"end":74},"obj":"Protein"},{"id":"T8995","span":{"begin":56,"end":60},"obj":"Protein"},{"id":"T8909","span":{"begin":498,"end":502},"obj":"Protein"},{"id":"T8908","span":{"begin":479,"end":485},"obj":"Protein"},{"id":"T8907","span":{"begin":321,"end":325},"obj":"Protein"},{"id":"T8906","span":{"begin":175,"end":179},"obj":"Protein"},{"id":"T8905","span":{"begin":70,"end":74},"obj":"Protein"},{"id":"T8904","span":{"begin":56,"end":60},"obj":"Protein"}],"relations":[{"id":"R5918","pred":"themeOf","subj":"T8998","obj":"T8997"}],"text":"Our data thus show significant clinical implications of CCR5, because CCR5 is a G protein–coupled receptor and it is amenable to use as a small molecule for the inhibition of CCR5. Several such compounds have already been shown to be safe in clinical trials for use in certain diseases such as HIV [53]. Thus, we believe CCR5 is a cancer target that warrants continued investigation. In summary, this study showed that melanoma cells growth was inhibited via modulation of NF-κB/IL-1Ra pathways in CCR5−/− mice."}

{"project":"testone","denotations":[{"id":"T8816","span":{"begin":498,"end":502},"obj":"Protein"},{"id":"T8815","span":{"begin":479,"end":485},"obj":"Protein"},{"id":"T8814","span":{"begin":321,"end":325},"obj":"Protein"},{"id":"T8813","span":{"begin":175,"end":179},"obj":"Protein"},{"id":"T8812","span":{"begin":70,"end":74},"obj":"Protein"},{"id":"T8811","span":{"begin":56,"end":60},"obj":"Protein"}],"text":"Our data thus show significant clinical implications of CCR5, because CCR5 is a G protein–coupled receptor and it is amenable to use as a small molecule for the inhibition of CCR5. Several such compounds have already been shown to be safe in clinical trials for use in certain diseases such as HIV [53]. Thus, we believe CCR5 is a cancer target that warrants continued investigation. In summary, this study showed that melanoma cells growth was inhibited via modulation of NF-κB/IL-1Ra pathways in CCR5−/− mice."}

{"project":"BioNLP16_Messiy","denotations":[{"id":"T11196","span":{"begin":161,"end":171},"obj":"Negative_regulation"},{"id":"T11171","span":{"begin":498,"end":502},"obj":"Protein"},{"id":"T11170","span":{"begin":479,"end":485},"obj":"Protein"},{"id":"T11169","span":{"begin":321,"end":325},"obj":"Protein"},{"id":"T11168","span":{"begin":175,"end":179},"obj":"Protein"},{"id":"T11167","span":{"begin":70,"end":74},"obj":"Protein"},{"id":"T11166","span":{"begin":56,"end":60},"obj":"Protein"}],"relations":[{"id":"R7418","pred":"themeOf","subj":"T11168","obj":"T11196"}],"text":"Our data thus show significant clinical implications of CCR5, because CCR5 is a G protein–coupled receptor and it is amenable to use as a small molecule for the inhibition of CCR5. Several such compounds have already been shown to be safe in clinical trials for use in certain diseases such as HIV [53]. Thus, we believe CCR5 is a cancer target that warrants continued investigation. In summary, this study showed that melanoma cells growth was inhibited via modulation of NF-κB/IL-1Ra pathways in CCR5−/− mice."}

{"project":"BioNLP16_DUT","denotations":[{"id":"T10842","span":{"begin":479,"end":485},"obj":"Protein"},{"id":"T10841","span":{"begin":321,"end":325},"obj":"Protein"},{"id":"T10840","span":{"begin":175,"end":179},"obj":"Protein"},{"id":"T10839","span":{"begin":70,"end":74},"obj":"Protein"},{"id":"T10838","span":{"begin":56,"end":60},"obj":"Protein"},{"id":"T10870","span":{"begin":161,"end":171},"obj":"Negative_regulation"},{"id":"T10843","span":{"begin":498,"end":502},"obj":"Protein"}],"relations":[{"id":"R7326","pred":"themeOf","subj":"T10840","obj":"T10870"}],"text":"Our data thus show significant clinical implications of CCR5, because CCR5 is a G protein–coupled receptor and it is amenable to use as a small molecule for the inhibition of CCR5. Several such compounds have already been shown to be safe in clinical trials for use in certain diseases such as HIV [53]. Thus, we believe CCR5 is a cancer target that warrants continued investigation. In summary, this study showed that melanoma cells growth was inhibited via modulation of NF-κB/IL-1Ra pathways in CCR5−/− mice."}

{"project":"2_test","denotations":[{"id":"22567084-12788340-91707059","span":{"begin":299,"end":301},"obj":"12788340"}],"text":"Our data thus show significant clinical implications of CCR5, because CCR5 is a G protein–coupled receptor and it is amenable to use as a small molecule for the inhibition of CCR5. Several such compounds have already been shown to be safe in clinical trials for use in certain diseases such as HIV [53]. Thus, we believe CCR5 is a cancer target that warrants continued investigation. In summary, this study showed that melanoma cells growth was inhibited via modulation of NF-κB/IL-1Ra pathways in CCR5−/− mice."}

{"project":"pmc-enju-pas","denotations":[{"id":"T10734","span":{"begin":506,"end":510},"obj":"NN"},{"id":"T10733","span":{"begin":498,"end":505},"obj":"NN"},{"id":"T10732","span":{"begin":495,"end":497},"obj":"IN"},{"id":"T10731","span":{"begin":486,"end":494},"obj":"NN"},{"id":"T10730","span":{"begin":473,"end":485},"obj":"NN"},{"id":"T10729","span":{"begin":470,"end":472},"obj":"IN"},{"id":"T10728","span":{"begin":459,"end":469},"obj":"NN"},{"id":"T10727","span":{"begin":455,"end":458},"obj":"IN"},{"id":"T10726","span":{"begin":445,"end":454},"obj":"VB"},{"id":"T10725","span":{"begin":441,"end":444},"obj":"VB"},{"id":"T10724","span":{"begin":434,"end":440},"obj":"NN"},{"id":"T10723","span":{"begin":428,"end":433},"obj":"NN"},{"id":"T10722","span":{"begin":419,"end":427},"obj":"NN"},{"id":"T10721","span":{"begin":414,"end":418},"obj":"IN"},{"id":"T10720","span":{"begin":407,"end":413},"obj":"VB"},{"id":"T10719","span":{"begin":401,"end":406},"obj":"NN"},{"id":"T10718","span":{"begin":396,"end":400},"obj":"DT"},{"id":"T10717","span":{"begin":394,"end":395},"obj":"-COMMA-"},{"id":"T10716","span":{"begin":387,"end":394},"obj":"NN"},{"id":"T10715","span":{"begin":384,"end":386},"obj":"IN"},{"id":"T10714","span":{"begin":369,"end":382},"obj":"NN"},{"id":"T10713","span":{"begin":359,"end":368},"obj":"JJ"},{"id":"T10712","span":{"begin":350,"end":358},"obj":"VB"},{"id":"T10711","span":{"begin":345,"end":349},"obj":"WDT"},{"id":"T10710","span":{"begin":338,"end":344},"obj":"NN"},{"id":"T10709","span":{"begin":331,"end":337},"obj":"NN"},{"id":"T10708","span":{"begin":329,"end":330},"obj":"DT"},{"id":"T10707","span":{"begin":326,"end":328},"obj":"VB"},{"id":"T10706","span":{"begin":321,"end":325},"obj":"NN"},{"id":"T10705","span":{"begin":313,"end":320},"obj":"VB"},{"id":"T10704","span":{"begin":310,"end":312},"obj":"PRP"},{"id":"T10703","span":{"begin":308,"end":309},"obj":"-COMMA-"},{"id":"T10702","span":{"begin":304,"end":308},"obj":"RB"},{"id":"T10701","span":{"begin":301,"end":302},"obj":"-RRB-"},{"id":"T10700","span":{"begin":299,"end":301},"obj":"CD"},{"id":"T10699","span":{"begin":298,"end":299},"obj":"-LRB-"},{"id":"T10698","span":{"begin":294,"end":297},"obj":"NN"},{"id":"T10697","span":{"begin":291,"end":293},"obj":"IN"},{"id":"T10696","span":{"begin":286,"end":290},"obj":"JJ"},{"id":"T10695","span":{"begin":277,"end":285},"obj":"NN"},{"id":"T10694","span":{"begin":269,"end":276},"obj":"JJ"},{"id":"T10693","span":{"begin":266,"end":268},"obj":"IN"},{"id":"T10692","span":{"begin":262,"end":265},"obj":"NN"},{"id":"T10691","span":{"begin":258,"end":261},"obj":"IN"},{"id":"T10690","span":{"begin":251,"end":257},"obj":"NN"},{"id":"T10689","span":{"begin":242,"end":250},"obj":"JJ"},{"id":"T10688","span":{"begin":239,"end":241},"obj":"IN"},{"id":"T10687","span":{"begin":234,"end":238},"obj":"JJ"},{"id":"T10686","span":{"begin":231,"end":233},"obj":"VB"},{"id":"T10685","span":{"begin":228,"end":230},"obj":"TO"},{"id":"T10684","span":{"begin":222,"end":227},"obj":"VB"},{"id":"T10683","span":{"begin":217,"end":221},"obj":"VB"},{"id":"T10682","span":{"begin":209,"end":216},"obj":"RB"},{"id":"T10681","span":{"begin":204,"end":208},"obj":"VB"},{"id":"T10680","span":{"begin":194,"end":203},"obj":"NN"},{"id":"T10679","span":{"begin":189,"end":193},"obj":"JJ"},{"id":"T10678","span":{"begin":181,"end":188},"obj":"JJ"},{"id":"T10677","span":{"begin":175,"end":179},"obj":"NN"},{"id":"T10676","span":{"begin":172,"end":174},"obj":"IN"},{"id":"T10675","span":{"begin":161,"end":171},"obj":"NN"},{"id":"T10674","span":{"begin":157,"end":160},"obj":"DT"},{"id":"T10673","span":{"begin":153,"end":156},"obj":"IN"},{"id":"T10672","span":{"begin":144,"end":152},"obj":"NN"},{"id":"T10671","span":{"begin":138,"end":143},"obj":"JJ"},{"id":"T10670","span":{"begin":136,"end":137},"obj":"DT"},{"id":"T10669","span":{"begin":133,"end":135},"obj":"IN"},{"id":"T10668","span":{"begin":129,"end":132},"obj":"VB"},{"id":"T10667","span":{"begin":126,"end":128},"obj":"TO"},{"id":"T10666","span":{"begin":117,"end":125},"obj":"JJ"},{"id":"T10665","span":{"begin":114,"end":116},"obj":"VB"},{"id":"T10664","span":{"begin":111,"end":113},"obj":"PRP"},{"id":"T10663","span":{"begin":107,"end":110},"obj":"CC"},{"id":"T10662","span":{"begin":98,"end":106},"obj":"NN"},{"id":"T10661","span":{"begin":82,"end":97},"obj":"VB"},{"id":"T10660","span":{"begin":80,"end":81},"obj":"NN"},{"id":"T10659","span":{"begin":78,"end":79},"obj":"DT"},{"id":"T10658","span":{"begin":75,"end":77},"obj":"VB"},{"id":"T10657","span":{"begin":70,"end":74},"obj":"NN"},{"id":"T10656","span":{"begin":62,"end":69},"obj":"IN"},{"id":"T10655","span":{"begin":60,"end":61},"obj":"-COMMA-"},{"id":"T10654","span":{"begin":56,"end":60},"obj":"NN"},{"id":"T10653","span":{"begin":53,"end":55},"obj":"IN"},{"id":"T10652","span":{"begin":40,"end":52},"obj":"NN"},{"id":"T10651","span":{"begin":31,"end":39},"obj":"JJ"},{"id":"T10650","span":{"begin":19,"end":30},"obj":"JJ"},{"id":"T10649","span":{"begin":14,"end":18},"obj":"VB"},{"id":"T10648","span":{"begin":9,"end":13},"obj":"RB"},{"id":"T10647","span":{"begin":4,"end":8},"obj":"NN"},{"id":"T10646","span":{"begin":0,"end":3},"obj":"PRP-DOLLAR-"}],"relations":[{"id":"R7212","pred":"arg1Of","subj":"T10647","obj":"T10646"},{"id":"R7213","pred":"arg1Of","subj":"T10647","obj":"T10649"},{"id":"R7214","pred":"arg1Of","subj":"T10649","obj":"T10648"},{"id":"R7215","pred":"arg1Of","subj":"T10649","obj":"T10655"},{"id":"R7216","pred":"arg1Of","subj":"T10649","obj":"T10656"},{"id":"R7217","pred":"arg1Of","subj":"T10651","obj":"T10650"},{"id":"R7218","pred":"arg2Of","subj":"T10652","obj":"T10649"},{"id":"R7219","pred":"arg1Of","subj":"T10652","obj":"T10651"},{"id":"R7220","pred":"arg1Of","subj":"T10652","obj":"T10653"},{"id":"R7221","pred":"arg2Of","subj":"T10654","obj":"T10653"},{"id":"R7222","pred":"arg1Of","subj":"T10657","obj":"T10658"},{"id":"R7223","pred":"arg1Of","subj":"T10658","obj":"T10663"},{"id":"R7224","pred":"arg1Of","subj":"T10661","obj":"T10660"},{"id":"R7225","pred":"arg2Of","subj":"T10662","obj":"T10658"},{"id":"R7226","pred":"arg1Of","subj":"T10662","obj":"T10659"},{"id":"R7227","pred":"arg1Of","subj":"T10662","obj":"T10661"},{"id":"R7228","pred":"arg2Of","subj":"T10663","obj":"T10656"},{"id":"R7229","pred":"arg1Of","subj":"T10664","obj":"T10665"},{"id":"R7230","pred":"arg1Of","subj":"T10664","obj":"T10666"},{"id":"R7231","pred":"arg2Of","subj":"T10664","obj":"T10668"},{"id":"R7232","pred":"arg2Of","subj":"T10665","obj":"T10663"},{"id":"R7233","pred":"arg2Of","subj":"T10666","obj":"T10665"},{"id":"R7234","pred":"arg2Of","subj":"T10668","obj":"T10666"},{"id":"R7235","pred":"arg1Of","subj":"T10668","obj":"T10667"},{"id":"R7236","pred":"arg1Of","subj":"T10668","obj":"T10669"},{"id":"R7237","pred":"arg2Of","subj":"T10672","obj":"T10669"},{"id":"R7238","pred":"arg1Of","subj":"T10672","obj":"T10670"},{"id":"R7239","pred":"arg1Of","subj":"T10672","obj":"T10671"},{"id":"R7240","pred":"arg1Of","subj":"T10672","obj":"T10673"},{"id":"R7241","pred":"arg2Of","subj":"T10675","obj":"T10673"},{"id":"R7242","pred":"arg1Of","subj":"T10675","obj":"T10674"},{"id":"R7243","pred":"arg1Of","subj":"T10675","obj":"T10676"},{"id":"R7244","pred":"arg2Of","subj":"T10677","obj":"T10676"},{"id":"R7245","pred":"arg1Of","subj":"T10680","obj":"T10678"},{"id":"R7246","pred":"arg1Of","subj":"T10680","obj":"T10679"},{"id":"R7247","pred":"arg1Of","subj":"T10680","obj":"T10681"},{"id":"R7248","pred":"arg1Of","subj":"T10680","obj":"T10683"},{"id":"R7249","pred":"arg2Of","subj":"T10680","obj":"T10684"},{"id":"R7250","pred":"arg1Of","subj":"T10680","obj":"T10686"},{"id":"R7251","pred":"arg1Of","subj":"T10680","obj":"T10687"},{"id":"R7252","pred":"arg2Of","subj":"T10684","obj":"T10681"},{"id":"R7253","pred":"arg1Of","subj":"T10684","obj":"T10682"},{"id":"R7254","pred":"arg2Of","subj":"T10684","obj":"T10683"},{"id":"R7255","pred":"arg3Of","subj":"T10686","obj":"T10684"},{"id":"R7256","pred":"arg1Of","subj":"T10686","obj":"T10685"},{"id":"R7257","pred":"arg2Of","subj":"T10687","obj":"T10686"},{"id":"R7258","pred":"arg1Of","subj":"T10687","obj":"T10688"},{"id":"R7259","pred":"arg2Of","subj":"T10690","obj":"T10688"},{"id":"R7260","pred":"arg1Of","subj":"T10690","obj":"T10689"},{"id":"R7261","pred":"arg1Of","subj":"T10690","obj":"T10691"},{"id":"R7262","pred":"arg2Of","subj":"T10692","obj":"T10691"},{"id":"R7263","pred":"arg1Of","subj":"T10692","obj":"T10693"},{"id":"R7264","pred":"arg2Of","subj":"T10695","obj":"T10693"},{"id":"R7265","pred":"arg1Of","subj":"T10695","obj":"T10694"},{"id":"R7266","pred":"arg1Of","subj":"T10695","obj":"T10697"},{"id":"R7267","pred":"arg1Of","subj":"T10697","obj":"T10696"},{"id":"R7268","pred":"arg2Of","subj":"T10698","obj":"T10697"},{"id":"R7269","pred":"arg1Of","subj":"T10698","obj":"T10699"},{"id":"R7270","pred":"arg2Of","subj":"T10700","obj":"T10699"},{"id":"R7271","pred":"arg3Of","subj":"T10701","obj":"T10699"},{"id":"R7272","pred":"arg1Of","subj":"T10704","obj":"T10705"},{"id":"R7273","pred":"arg1Of","subj":"T10705","obj":"T10702"},{"id":"R7274","pred":"arg1Of","subj":"T10705","obj":"T10703"},{"id":"R7275","pred":"arg1Of","subj":"T10706","obj":"T10707"},{"id":"R7276","pred":"arg2Of","subj":"T10707","obj":"T10705"},{"id":"R7277","pred":"arg2Of","subj":"T10710","obj":"T10707"},{"id":"R7278","pred":"arg1Of","subj":"T10710","obj":"T10708"},{"id":"R7279","pred":"arg1Of","subj":"T10710","obj":"T10709"},{"id":"R7280","pred":"arg1Of","subj":"T10710","obj":"T10711"},{"id":"R7281","pred":"arg1Of","subj":"T10710","obj":"T10712"},{"id":"R7282","pred":"arg2Of","subj":"T10714","obj":"T10712"},{"id":"R7283","pred":"arg1Of","subj":"T10714","obj":"T10713"},{"id":"R7284","pred":"arg2Of","subj":"T10716","obj":"T10715"},{"id":"R7285","pred":"arg1Of","subj":"T10719","obj":"T10718"},{"id":"R7286","pred":"arg1Of","subj":"T10719","obj":"T10720"},{"id":"R7287","pred":"arg1Of","subj":"T10720","obj":"T10715"},{"id":"R7288","pred":"arg1Of","subj":"T10720","obj":"T10717"},{"id":"R7289","pred":"arg1Of","subj":"T10724","obj":"T10722"},{"id":"R7290","pred":"arg1Of","subj":"T10724","obj":"T10723"},{"id":"R7291","pred":"arg1Of","subj":"T10724","obj":"T10725"},{"id":"R7292","pred":"arg2Of","subj":"T10724","obj":"T10726"},{"id":"R7293","pred":"arg2Of","subj":"T10726","obj":"T10720"},{"id":"R7294","pred":"arg1Of","subj":"T10726","obj":"T10721"},{"id":"R7295","pred":"arg2Of","subj":"T10726","obj":"T10725"},{"id":"R7296","pred":"arg1Of","subj":"T10726","obj":"T10727"},{"id":"R7297","pred":"arg2Of","subj":"T10728","obj":"T10727"},{"id":"R7298","pred":"arg1Of","subj":"T10728","obj":"T10729"},{"id":"R7299","pred":"arg2Of","subj":"T10731","obj":"T10729"},{"id":"R7300","pred":"arg1Of","subj":"T10731","obj":"T10730"},{"id":"R7301","pred":"arg1Of","subj":"T10731","obj":"T10732"},{"id":"R7302","pred":"arg2Of","subj":"T10734","obj":"T10732"},{"id":"R7303","pred":"arg1Of","subj":"T10734","obj":"T10733"}],"namespaces":[{"prefix":"_base","uri":"http://kmcs.nii.ac.jp/enju/"}],"text":"Our data thus show significant clinical implications of CCR5, because CCR5 is a G protein–coupled receptor and it is amenable to use as a small molecule for the inhibition of CCR5. Several such compounds have already been shown to be safe in clinical trials for use in certain diseases such as HIV [53]. Thus, we believe CCR5 is a cancer target that warrants continued investigation. In summary, this study showed that melanoma cells growth was inhibited via modulation of NF-κB/IL-1Ra pathways in CCR5−/− mice."}

{"project":"bionlp-st-ge-2016-test-proteins","denotations":[{"id":"T9218","span":{"begin":498,"end":502},"obj":"Protein"},{"id":"T9217","span":{"begin":479,"end":485},"obj":"Protein"},{"id":"T9216","span":{"begin":321,"end":325},"obj":"Protein"},{"id":"T9215","span":{"begin":175,"end":179},"obj":"Protein"},{"id":"T9214","span":{"begin":70,"end":74},"obj":"Protein"},{"id":"T9213","span":{"begin":56,"end":60},"obj":"Protein"}],"namespaces":[{"prefix":"_base","uri":"http://bionlp.dbcls.jp/ontology/ge.owl#"}],"text":"Our data thus show significant clinical implications of CCR5, because CCR5 is a G protein–coupled receptor and it is amenable to use as a small molecule for the inhibition of CCR5. Several such compounds have already been shown to be safe in clinical trials for use in certain diseases such as HIV [53]. Thus, we believe CCR5 is a cancer target that warrants continued investigation. In summary, this study showed that melanoma cells growth was inhibited via modulation of NF-κB/IL-1Ra pathways in CCR5−/− mice."}

{"project":"bionlp-st-ge-2016-uniprot","denotations":[{"id":"T10918","span":{"begin":479,"end":485},"obj":"http://www.uniprot.org/uniprot/P18510"},{"id":"T10902","span":{"begin":498,"end":502},"obj":"http://www.uniprot.org/uniprot/P51681"},{"id":"T10901","span":{"begin":321,"end":325},"obj":"http://www.uniprot.org/uniprot/P51681"},{"id":"T10900","span":{"begin":175,"end":179},"obj":"http://www.uniprot.org/uniprot/P51681"},{"id":"T10899","span":{"begin":70,"end":74},"obj":"http://www.uniprot.org/uniprot/P51681"},{"id":"T10898","span":{"begin":56,"end":60},"obj":"http://www.uniprot.org/uniprot/P51681"}],"namespaces":[{"prefix":"_base","uri":"http://www.uniprot.org/uniprot/"}],"text":"Our data thus show significant clinical implications of CCR5, because CCR5 is a G protein–coupled receptor and it is amenable to use as a small molecule for the inhibition of CCR5. Several such compounds have already been shown to be safe in clinical trials for use in certain diseases such as HIV [53]. Thus, we believe CCR5 is a cancer target that warrants continued investigation. In summary, this study showed that melanoma cells growth was inhibited via modulation of NF-κB/IL-1Ra pathways in CCR5−/− mice."}

{"project":"GO-BP","denotations":[{"id":"T9243","span":{"begin":428,"end":440},"obj":"http://purl.obolibrary.org/obo/GO_0016049"},{"id":"T9234","span":{"begin":434,"end":440},"obj":"http://purl.obolibrary.org/obo/GO_0040007"}],"text":"Our data thus show significant clinical implications of CCR5, because CCR5 is a G protein–coupled receptor and it is amenable to use as a small molecule for the inhibition of CCR5. Several such compounds have already been shown to be safe in clinical trials for use in certain diseases such as HIV [53]. Thus, we believe CCR5 is a cancer target that warrants continued investigation. In summary, this study showed that melanoma cells growth was inhibited via modulation of NF-κB/IL-1Ra pathways in CCR5−/− mice."}

{"project":"GO-CC","denotations":[{"id":"T9309","span":{"begin":428,"end":433},"obj":"http://purl.obolibrary.org/obo/GO_0005623"}],"text":"Our data thus show significant clinical implications of CCR5, because CCR5 is a G protein–coupled receptor and it is amenable to use as a small molecule for the inhibition of CCR5. Several such compounds have already been shown to be safe in clinical trials for use in certain diseases such as HIV [53]. Thus, we believe CCR5 is a cancer target that warrants continued investigation. In summary, this study showed that melanoma cells growth was inhibited via modulation of NF-κB/IL-1Ra pathways in CCR5−/− mice."}

{"project":"sentences","denotations":[{"id":"T9058","span":{"begin":384,"end":511},"obj":"Sentence"},{"id":"T9057","span":{"begin":304,"end":383},"obj":"Sentence"},{"id":"T9056","span":{"begin":181,"end":303},"obj":"Sentence"},{"id":"T9055","span":{"begin":0,"end":180},"obj":"Sentence"},{"id":"T197","span":{"begin":0,"end":180},"obj":"Sentence"},{"id":"T198","span":{"begin":181,"end":303},"obj":"Sentence"},{"id":"T199","span":{"begin":304,"end":383},"obj":"Sentence"},{"id":"T200","span":{"begin":384,"end":511},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Our data thus show significant clinical implications of CCR5, because CCR5 is a G protein–coupled receptor and it is amenable to use as a small molecule for the inhibition of CCR5. Several such compounds have already been shown to be safe in clinical trials for use in certain diseases such as HIV [53]. Thus, we believe CCR5 is a cancer target that warrants continued investigation. In summary, this study showed that melanoma cells growth was inhibited via modulation of NF-κB/IL-1Ra pathways in CCR5−/− mice."}

{"project":"simple1","denotations":[{"id":"T9411","span":{"begin":498,"end":502},"obj":"Protein"},{"id":"T9410","span":{"begin":479,"end":485},"obj":"Protein"},{"id":"T9409","span":{"begin":321,"end":325},"obj":"Protein"},{"id":"T9408","span":{"begin":175,"end":179},"obj":"Protein"},{"id":"T9407","span":{"begin":70,"end":74},"obj":"Protein"},{"id":"T9406","span":{"begin":56,"end":60},"obj":"Protein"}],"text":"Our data thus show significant clinical implications of CCR5, because CCR5 is a G protein–coupled receptor and it is amenable to use as a small molecule for the inhibition of CCR5. Several such compounds have already been shown to be safe in clinical trials for use in certain diseases such as HIV [53]. Thus, we believe CCR5 is a cancer target that warrants continued investigation. In summary, this study showed that melanoma cells growth was inhibited via modulation of NF-κB/IL-1Ra pathways in CCR5−/− mice."}

{"project":"DLUT931","denotations":[{"id":"T11032","span":{"begin":161,"end":171},"obj":"Negative_regulation"},{"id":"T11000","span":{"begin":498,"end":502},"obj":"Protein"},{"id":"T10999","span":{"begin":479,"end":485},"obj":"Protein"},{"id":"T10998","span":{"begin":321,"end":325},"obj":"Protein"},{"id":"T10997","span":{"begin":175,"end":179},"obj":"Protein"},{"id":"T10996","span":{"begin":70,"end":74},"obj":"Protein"},{"id":"T10995","span":{"begin":56,"end":60},"obj":"Protein"}],"relations":[{"id":"R7369","pred":"themeOf","subj":"T10997","obj":"T11032"}],"text":"Our data thus show significant clinical implications of CCR5, because CCR5 is a G protein–coupled receptor and it is amenable to use as a small molecule for the inhibition of CCR5. Several such compounds have already been shown to be safe in clinical trials for use in certain diseases such as HIV [53]. Thus, we believe CCR5 is a cancer target that warrants continued investigation. In summary, this study showed that melanoma cells growth was inhibited via modulation of NF-κB/IL-1Ra pathways in CCR5−/− mice."}

{"project":"bionlp-st-ge-2016-test-ihmc","denotations":[{"id":"T11678","span":{"begin":157,"end":179},"obj":"Negative_regulation"},{"id":"T11648","span":{"begin":53,"end":60},"obj":"Protein"},{"id":"T11633","span":{"begin":70,"end":74},"obj":"Protein"},{"id":"T11599","span":{"begin":506,"end":510},"obj":"Protein"},{"id":"T11572","span":{"begin":136,"end":179},"obj":"Entity"},{"id":"T11561","span":{"begin":321,"end":325},"obj":"Protein"},{"id":"T11556","span":{"begin":78,"end":106},"obj":"Protein"},{"id":"T11548","span":{"begin":470,"end":494},"obj":"Protein"},{"id":"T11514","span":{"begin":479,"end":485},"obj":"Protein"},{"id":"T11508","span":{"begin":172,"end":179},"obj":"Protein"},{"id":"T11498","span":{"begin":419,"end":440},"obj":"Entity"}],"relations":[{"id":"R7553","pred":"themeOf","subj":"T11508","obj":"T11678"}],"text":"Our data thus show significant clinical implications of CCR5, because CCR5 is a G protein–coupled receptor and it is amenable to use as a small molecule for the inhibition of CCR5. Several such compounds have already been shown to be safe in clinical trials for use in certain diseases such as HIV [53]. Thus, we believe CCR5 is a cancer target that warrants continued investigation. In summary, this study showed that melanoma cells growth was inhibited via modulation of NF-κB/IL-1Ra pathways in CCR5−/− mice."}

{"project":"bionlp-st-ge-2016-spacy-parsed","denotations":[{"id":"T13143","span":{"begin":510,"end":511},"obj":"."},{"id":"T13142","span":{"begin":506,"end":510},"obj":"NNS"},{"id":"T13141","span":{"begin":504,"end":505},"obj":"NN"},{"id":"T13140","span":{"begin":503,"end":504},"obj":"NN"},{"id":"T13139","span":{"begin":502,"end":503},"obj":"CD"},{"id":"T13138","span":{"begin":498,"end":502},"obj":"CD"},{"id":"T13137","span":{"begin":495,"end":497},"obj":"IN"},{"id":"T13136","span":{"begin":486,"end":494},"obj":"NNS"},{"id":"T13135","span":{"begin":479,"end":485},"obj":"NNP"},{"id":"T13134","span":{"begin":478,"end":479},"obj":"NNP"},{"id":"T13133","span":{"begin":473,"end":478},"obj":"NNP"},{"id":"T13132","span":{"begin":470,"end":472},"obj":"IN"},{"id":"T13131","span":{"begin":459,"end":469},"obj":"NN"},{"id":"T13130","span":{"begin":455,"end":458},"obj":"IN"},{"id":"T13129","span":{"begin":445,"end":454},"obj":"VBN"},{"id":"T13128","span":{"begin":441,"end":444},"obj":"VBD"},{"id":"T13127","span":{"begin":434,"end":440},"obj":"NN"},{"id":"T13126","span":{"begin":428,"end":433},"obj":"NNS"},{"id":"T13125","span":{"begin":419,"end":427},"obj":"NN"},{"id":"T13124","span":{"begin":414,"end":418},"obj":"IN"},{"id":"T13123","span":{"begin":407,"end":413},"obj":"VBD"},{"id":"T13122","span":{"begin":401,"end":406},"obj":"NN"},{"id":"T13121","span":{"begin":396,"end":400},"obj":"DT"},{"id":"T13120","span":{"begin":394,"end":395},"obj":","},{"id":"T13119","span":{"begin":387,"end":394},"obj":"NN"},{"id":"T13118","span":{"begin":384,"end":386},"obj":"IN"},{"id":"T13117","span":{"begin":382,"end":383},"obj":"."},{"id":"T13116","span":{"begin":369,"end":382},"obj":"NN"},{"id":"T13115","span":{"begin":359,"end":368},"obj":"VBN"},{"id":"T13114","span":{"begin":350,"end":358},"obj":"VBZ"},{"id":"T13113","span":{"begin":345,"end":349},"obj":"WDT"},{"id":"T13112","span":{"begin":338,"end":344},"obj":"NN"},{"id":"T13111","span":{"begin":331,"end":337},"obj":"NN"},{"id":"T13110","span":{"begin":329,"end":330},"obj":"DT"},{"id":"T13109","span":{"begin":326,"end":328},"obj":"VBZ"},{"id":"T13108","span":{"begin":321,"end":325},"obj":"NNP"},{"id":"T13107","span":{"begin":313,"end":320},"obj":"VBP"},{"id":"T13106","span":{"begin":310,"end":312},"obj":"PRP"},{"id":"T13105","span":{"begin":308,"end":309},"obj":","},{"id":"T13104","span":{"begin":304,"end":308},"obj":"RB"},{"id":"T13103","span":{"begin":302,"end":303},"obj":"."},{"id":"T13102","span":{"begin":301,"end":302},"obj":"NNP"},{"id":"T13101","span":{"begin":299,"end":301},"obj":"CD"},{"id":"T13100","span":{"begin":298,"end":299},"obj":"NNP"},{"id":"T13099","span":{"begin":294,"end":297},"obj":"NNP"},{"id":"T13098","span":{"begin":291,"end":293},"obj":"IN"},{"id":"T13097","span":{"begin":286,"end":290},"obj":"JJ"},{"id":"T13096","span":{"begin":277,"end":285},"obj":"NNS"},{"id":"T13095","span":{"begin":269,"end":276},"obj":"JJ"},{"id":"T13094","span":{"begin":266,"end":268},"obj":"IN"},{"id":"T13093","span":{"begin":262,"end":265},"obj":"NN"},{"id":"T13092","span":{"begin":258,"end":261},"obj":"IN"},{"id":"T13091","span":{"begin":251,"end":257},"obj":"NNS"},{"id":"T13090","span":{"begin":242,"end":250},"obj":"JJ"},{"id":"T13089","span":{"begin":239,"end":241},"obj":"IN"},{"id":"T13088","span":{"begin":234,"end":238},"obj":"JJ"},{"id":"T13087","span":{"begin":231,"end":233},"obj":"VB"},{"id":"T13086","span":{"begin":228,"end":230},"obj":"TO"},{"id":"T13085","span":{"begin":222,"end":227},"obj":"VBN"},{"id":"T13084","span":{"begin":217,"end":221},"obj":"VBN"},{"id":"T13083","span":{"begin":209,"end":216},"obj":"RB"},{"id":"T13082","span":{"begin":204,"end":208},"obj":"VBP"},{"id":"T13081","span":{"begin":194,"end":203},"obj":"NNS"},{"id":"T13080","span":{"begin":189,"end":193},"obj":"JJ"},{"id":"T13079","span":{"begin":181,"end":188},"obj":"JJ"},{"id":"T13078","span":{"begin":179,"end":180},"obj":"."},{"id":"T13077","span":{"begin":175,"end":179},"obj":"NNP"},{"id":"T13076","span":{"begin":172,"end":174},"obj":"IN"},{"id":"T13075","span":{"begin":161,"end":171},"obj":"NN"},{"id":"T13074","span":{"begin":157,"end":160},"obj":"DT"},{"id":"T13073","span":{"begin":153,"end":156},"obj":"IN"},{"id":"T13072","span":{"begin":144,"end":152},"obj":"NN"},{"id":"T13071","span":{"begin":138,"end":143},"obj":"JJ"},{"id":"T13070","span":{"begin":136,"end":137},"obj":"DT"},{"id":"T13069","span":{"begin":133,"end":135},"obj":"IN"},{"id":"T13068","span":{"begin":129,"end":132},"obj":"VB"},{"id":"T13067","span":{"begin":126,"end":128},"obj":"TO"},{"id":"T13066","span":{"begin":117,"end":125},"obj":"JJ"},{"id":"T13065","span":{"begin":114,"end":116},"obj":"VBZ"},{"id":"T13064","span":{"begin":111,"end":113},"obj":"PRP"},{"id":"T13063","span":{"begin":107,"end":110},"obj":"CC"},{"id":"T13062","span":{"begin":98,"end":106},"obj":"NN"},{"id":"T13061","span":{"begin":90,"end":97},"obj":"VBN"},{"id":"T13060","span":{"begin":82,"end":89},"obj":"NN"},{"id":"T13059","span":{"begin":80,"end":81},"obj":"NNP"},{"id":"T13058","span":{"begin":78,"end":79},"obj":"DT"},{"id":"T13057","span":{"begin":75,"end":77},"obj":"VBZ"},{"id":"T13056","span":{"begin":70,"end":74},"obj":"NNP"},{"id":"T13055","span":{"begin":62,"end":69},"obj":"IN"},{"id":"T13054","span":{"begin":60,"end":61},"obj":","},{"id":"T13053","span":{"begin":56,"end":60},"obj":"NNP"},{"id":"T13052","span":{"begin":53,"end":55},"obj":"IN"},{"id":"T13051","span":{"begin":40,"end":52},"obj":"NNS"},{"id":"T13050","span":{"begin":31,"end":39},"obj":"JJ"},{"id":"T13049","span":{"begin":19,"end":30},"obj":"JJ"},{"id":"T13048","span":{"begin":14,"end":18},"obj":"VBP"},{"id":"T13047","span":{"begin":9,"end":13},"obj":"RB"},{"id":"T13046","span":{"begin":4,"end":8},"obj":"NNS"},{"id":"T13045","span":{"begin":0,"end":3},"obj":"PRP$"}],"relations":[{"id":"R8897","pred":"ROOT","subj":"T13085","obj":"T13085"},{"id":"R8898","pred":"aux","subj":"T13086","obj":"T13087"},{"id":"R8900","pred":"xcomp","subj":"T13087","obj":"T13085"},{"id":"R8901","pred":"acomp","subj":"T13088","obj":"T13087"},{"id":"R8902","pred":"prep","subj":"T13089","obj":"T13088"},{"id":"R8904","pred":"amod","subj":"T13090","obj":"T13091"},{"id":"R8905","pred":"pobj","subj":"T13091","obj":"T13089"},{"id":"R8907","pred":"prep","subj":"T13092","obj":"T13087"},{"id":"R8908","pred":"pobj","subj":"T13093","obj":"T13092"},{"id":"R8909","pred":"prep","subj":"T13094","obj":"T13093"},{"id":"R8911","pred":"amod","subj":"T13095","obj":"T13096"},{"id":"R8912","pred":"pobj","subj":"T13096","obj":"T13094"},{"id":"R8913","pred":"amod","subj":"T13097","obj":"T13098"},{"id":"R8915","pred":"prep","subj":"T13098","obj":"T13096"},{"id":"R8916","pred":"compound","subj":"T13099","obj":"T13100"},{"id":"R8918","pred":"pobj","subj":"T13100","obj":"T13098"},{"id":"R8919","pred":"nummod","subj":"T13101","obj":"T13102"},{"id":"R8920","pred":"conj","subj":"T13102","obj":"T13100"},{"id":"R8922","pred":"punct","subj":"T13103","obj":"T13085"},{"id":"R8923","pred":"advmod","subj":"T13104","obj":"T13107"},{"id":"R8924","pred":"punct","subj":"T13105","obj":"T13107"},{"id":"R8926","pred":"nsubj","subj":"T13106","obj":"T13107"},{"id":"R8927","pred":"ROOT","subj":"T13107","obj":"T13107"},{"id":"R8928","pred":"nsubj","subj":"T13108","obj":"T13109"},{"id":"R8930","pred":"ccomp","subj":"T13109","obj":"T13107"},{"id":"R8931","pred":"det","subj":"T13110","obj":"T13112"},{"id":"R8932","pred":"compound","subj":"T13111","obj":"T13112"},{"id":"R8933","pred":"attr","subj":"T13112","obj":"T13109"},{"id":"R8935","pred":"dobj","subj":"T13113","obj":"T13116"},{"id":"R8936","pred":"nsubj","subj":"T13114","obj":"T13115"},{"id":"R8939","pred":"amod","subj":"T13115","obj":"T13116"},{"id":"R8943","pred":"appos","subj":"T13116","obj":"T13112"},{"id":"R8944","pred":"punct","subj":"T13117","obj":"T13107"},{"id":"R8945","pred":"prep","subj":"T13118","obj":"T13123"},{"id":"R8946","pred":"pobj","subj":"T13119","obj":"T13118"},{"id":"R8947","pred":"punct","subj":"T13120","obj":"T13123"},{"id":"R8949","pred":"det","subj":"T13121","obj":"T13122"},{"id":"R8950","pred":"nsubj","subj":"T13122","obj":"T13123"},{"id":"R8951","pred":"ROOT","subj":"T13123","obj":"T13123"},{"id":"R8952","pred":"mark","subj":"T13124","obj":"T13129"},{"id":"R8954","pred":"compound","subj":"T13125","obj":"T13126"},{"id":"R8955","pred":"compound","subj":"T13126","obj":"T13127"},{"id":"R8957","pred":"nsubjpass","subj":"T13127","obj":"T13129"},{"id":"R8958","pred":"auxpass","subj":"T13128","obj":"T13129"},{"id":"R8960","pred":"ccomp","subj":"T13129","obj":"T13123"},{"id":"R8961","pred":"prep","subj":"T13130","obj":"T13129"},{"id":"R8962","pred":"pobj","subj":"T13131","obj":"T13130"},{"id":"R8964","pred":"prep","subj":"T13132","obj":"T13131"},{"id":"R8965","pred":"compound","subj":"T13133","obj":"T13135"},{"id":"R8966","pred":"compound","subj":"T13134","obj":"T13135"},{"id":"R8968","pred":"compound","subj":"T13135","obj":"T13136"},{"id":"R8969","pred":"pobj","subj":"T13136","obj":"T13132"},{"id":"R8970","pred":"prep","subj":"T13137","obj":"T13129"},{"id":"R8972","pred":"nummod","subj":"T13138","obj":"T13142"},{"id":"R8973","pred":"nummod","subj":"T13139","obj":"T13142"},{"id":"R8974","pred":"nmod","subj":"T13140","obj":"T13142"},{"id":"R8976","pred":"compound","subj":"T13141","obj":"T13142"},{"id":"R8977","pred":"pobj","subj":"T13142","obj":"T13137"},{"id":"R8978","pred":"punct","subj":"T13143","obj":"T13123"},{"id":"R8994","pred":"poss","subj":"T13045","obj":"T13046"},{"id":"R8995","pred":"nsubj","subj":"T13046","obj":"T13048"},{"id":"R8996","pred":"advmod","subj":"T13047","obj":"T13048"},{"id":"R8997","pred":"ROOT","subj":"T13048","obj":"T13048"},{"id":"R8998","pred":"amod","subj":"T13049","obj":"T13051"},{"id":"R8999","pred":"amod","subj":"T13050","obj":"T13051"},{"id":"R9000","pred":"dobj","subj":"T13051","obj":"T13048"},{"id":"R9001","pred":"prep","subj":"T13052","obj":"T13051"},{"id":"R9002","pred":"pobj","subj":"T13053","obj":"T13052"},{"id":"R9003","pred":"punct","subj":"T13054","obj":"T13048"},{"id":"R9004","pred":"mark","subj":"T13055","obj":"T13057"},{"id":"R9005","pred":"nsubj","subj":"T13056","obj":"T13057"},{"id":"R9006","pred":"advcl","subj":"T13057","obj":"T13048"},{"id":"R9007","pred":"det","subj":"T13058","obj":"T13060"},{"id":"R9008","pred":"compound","subj":"T13059","obj":"T13060"},{"id":"R9009","pred":"attr","subj":"T13060","obj":"T13057"},{"id":"R9010","pred":"acl","subj":"T13061","obj":"T13060"},{"id":"R9011","pred":"dobj","subj":"T13062","obj":"T13061"},{"id":"R9012","pred":"cc","subj":"T13063","obj":"T13057"},{"id":"R9013","pred":"nsubj","subj":"T13064","obj":"T13065"},{"id":"R9014","pred":"conj","subj":"T13065","obj":"T13057"},{"id":"R9015","pred":"acomp","subj":"T13066","obj":"T13065"},{"id":"R9016","pred":"aux","subj":"T13067","obj":"T13068"},{"id":"R9017","pred":"xcomp","subj":"T13068","obj":"T13066"},{"id":"R9018","pred":"prep","subj":"T13069","obj":"T13068"},{"id":"R9019","pred":"det","subj":"T13070","obj":"T13072"},{"id":"R9020","pred":"amod","subj":"T13071","obj":"T13072"},{"id":"R9021","pred":"pobj","subj":"T13072","obj":"T13069"},{"id":"R9022","pred":"prep","subj":"T13073","obj":"T13072"},{"id":"R9023","pred":"det","subj":"T13074","obj":"T13075"},{"id":"R9024","pred":"pobj","subj":"T13075","obj":"T13073"},{"id":"R9025","pred":"prep","subj":"T13076","obj":"T13075"},{"id":"R9026","pred":"pobj","subj":"T13077","obj":"T13076"},{"id":"R9027","pred":"punct","subj":"T13078","obj":"T13048"},{"id":"R9028","pred":"amod","subj":"T13079","obj":"T13081"},{"id":"R9029","pred":"amod","subj":"T13080","obj":"T13081"},{"id":"R9030","pred":"nsubj","subj":"T13081","obj":"T13085"},{"id":"R9031","pred":"aux","subj":"T13082","obj":"T13085"},{"id":"R9032","pred":"advmod","subj":"T13083","obj":"T13085"},{"id":"R9033","pred":"auxpass","subj":"T13084","obj":"T13085"}],"text":"Our data thus show significant clinical implications of CCR5, because CCR5 is a G protein–coupled receptor and it is amenable to use as a small molecule for the inhibition of CCR5. Several such compounds have already been shown to be safe in clinical trials for use in certain diseases such as HIV [53]. Thus, we believe CCR5 is a cancer target that warrants continued investigation. In summary, this study showed that melanoma cells growth was inhibited via modulation of NF-κB/IL-1Ra pathways in CCR5−/− mice."}

{"project":"bionlp-st-ge-2016-test-tees","denotations":[{"id":"T11346","span":{"begin":479,"end":485},"obj":"Protein"},{"id":"T11345","span":{"begin":473,"end":478},"obj":"Protein"},{"id":"T11344","span":{"begin":161,"end":171},"obj":"Negative_regulation"},{"id":"T11343","span":{"begin":175,"end":179},"obj":"Protein"},{"id":"T11342","span":{"begin":80,"end":106},"obj":"Protein"},{"id":"T11341","span":{"begin":70,"end":74},"obj":"Protein"}],"relations":[{"id":"R7460","pred":"themeOf","subj":"T11343","obj":"T11344"}],"text":"Our data thus show significant clinical implications of CCR5, because CCR5 is a G protein–coupled receptor and it is amenable to use as a small molecule for the inhibition of CCR5. Several such compounds have already been shown to be safe in clinical trials for use in certain diseases such as HIV [53]. Thus, we believe CCR5 is a cancer target that warrants continued investigation. In summary, this study showed that melanoma cells growth was inhibited via modulation of NF-κB/IL-1Ra pathways in CCR5−/− mice."}